@article{TCR22758,
author = {Fei Chen and Xiao-Guang Wang and Li-Feng Qi and Juan-Fen Mo and Zheng-Xiang Zhong},
title = {A novel nanoprobe-based assay for detecting K-ras mutations in plasma and stool samples from patients with pancreatic cancer: value in diagnosis and prognosis evaluation},
journal = {Translational Cancer Research},
volume = {7},
number = {4},
year = {2018},
keywords = {},
abstract = {Background: To develop a novel nanoprobe-based assay for detecting K-ras mutations in plasma and stool samples from patients with pancreatic cancer, and assess its value in the diagnosis and prognosis evaluation of this malignancy.
Methods: Fifty-eight pancreatic cancer, 18 chronic pancreatitis, 7 pancreatic cystadenoma, 5 pancreatic cyst, 2 solid pseudopapillary tumor of the pancreas patients, who were treated at the Second Affiliated Hospital of Jiaxing University from June 2013 to October 2015. Thirty-one healthy volunteers were as normal controls. Blood and stool samples were collected from these subjects to detect the K-ras mutation status using a novel nanoprobe-based assay, assess its diagnostic accuracy and analysis the relation between the clinicopathological characteristics and survival in pancreatic cancer.
Results: The detection rates of K-ras mutations in stool and plasma samples from patients with pancreatic cancer were 79.3% and 43.1%, respectively, both of which were significantly higher than those for patients with benign pancreatic diseases (15.6% and 6.3%, respectively; P},
issn = {2219-6803}, url = {https://tcr.amegroups.org/article/view/22758}
}